Medis

Medis, a distinguished name in pharmaceutical manufacturing, has been a reliable provider of high-quality generic pharmaceuticals since 1985. Specializing in out-licensing, Medis offers an extensive portfolio of 185 generic pharmaceutical products, primarily in tablet, capsule, and injection forms. The company is dedicated to fostering enduring relationships with its partners through technical excellence and a commitment to confidentiality.

Operating with the full support of its parent company, Teva Pharmaceutical Industries Ltd., Medis leverages advanced development and manufacturing capabilities. The company boasts a growing range of specialist oncology products and product formulations, predominantly solid oral dosages. Medis develops these products in-house and provides comprehensive regulatory support to its customers, with a proven track record in securing regulatory approvals across more than 140 countries. The primary address for Medis is Dalshraun 1, Hafnarfjörður, Capital Region 220, IS. Additional locations include 27 Rue Ginoux, Paris, FR; 37 Epping Rd, Level 1, Macquarie Park, New South Wales 2113, AU; Wilhelm-Theodor-Römhild-Str. 14, Mainz, Mainz 55130, DE; Via Rodari, 9, Como, Lombardy 22100, IT; Marszałkowska street 111, 1st floor - Omni Office, Warszawa, Warsaw 00-102, PL; Calle Anabel Segura, 11, Edif Albatros B., Alcobendas, Community of Madrid 28108, ES; and Rua James Joule 92, São Paulo, SP 04576-080, BR.

Medis continues to build upon its legacy of over 35 years by enhancing its service offerings and expanding its global reach. Information regarding upcoming projects and further developments at Medis will be completed soon with the support of the company’s management. We invite the manager of Medis to create a customized and exclusive company showcase and product listing on our platform to further highlight their exceptional contributions to the pharmaceutical industry.